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REVIEW
Rapid metagenomics for diagnosis of bloodstream and respiratory tract nosocomial 
infections: current status and future prospects
Lluís Moragues-Solanasa, Riccardo Scottia and Justin O’Gradya,b
aQuadram Institute of Bioscience, Norwich Research Park, Norwich, Norfolk, UK; bNorwich Medical School, University of East Anglia, Norwich, 
Norfolk, UK
ABSTRACT
Introduction: Nosocomial infections represent a major problem for the health-care systems worldwide. 
Currently, diagnosis relies on microbiological culture, which is slow and has poor sensitivity. While 
waiting for a diagnosis, patients are treated with empiric broad spectrum antimicrobials, which are 
often inappropriate for the infecting pathogen. This results in poor patient outcomes, poor antimicro-
bial stewardship and increased costs for health-care systems.
Areas covered: Clinical metagenomics (CMg), the application of metagenomic sequencing for the 
diagnosis of infection, has the potential to become a viable alternative to culture that can offer rapid 
results with high accuracy. In this article, we review current CMg methods for the diagnosis of 
nosocomial bloodstream (BSI) and lower respiratory-tract infections (LRTI).
Expert opinion: CMg approaches are more accurate in LRTI compared to BSI. This is because BSIs are 
caused by low pathogen numbers in a high background of human cells. To overcome this, most 
approaches focus on cell-free DNA, but, to date, these tests are not accurate enough yet to replace 
blood culture. The higher pathogen numbers in LRTI samples make this a more suitable for CMg and 
accurate approaches have been developed, which are likely to be implemented in hospitals within the 
next 2–5 years.
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1. Introduction
Nosocomial or healthcare-associated infections, are infections 
that are not present before admission, but are acquired and 
develop while attending a healthcare facility, e.g. at a hospital 
[1]. Data on the prevalence of nosocomial infections suggest 
that they affect between 5% and 20% of all hospital patients 
globally and are a particular problem in intensive-care units 
(ICUs) where the global pooled incidence of nosocomial infec-
tion is approximately 34% [2]. Nosocomial infections are espe-
cially problematic in low- and middle-income countries with 
an incidence 3–4 higher than more developed countries. 
Nosocomial infections lead to increased antimicrobial resis-
tance, prolonged hospital stays and higher mortality rates. In 
Europe alone, the direct costs associated with nosocomial 
infections are estimated at approximately €7 billion 
every year [2,3].
The most frequent type of nosocomial infections affect the 
bloodstream (which can develop into severe sepsis or septic 
shock) and respiratory system (health-care-associated pneu-
monia) [2,4]. Meta-analysis revealed that, although there was 
variation among data from different continents, nosocomial 
infections were most commonly caused by Gram-negative 
species, particularly from the genera Acinetobacter, 
Pseudomonas, Escherichia and Klebsiella [2,5]. However, the 
Gram-positive genera Enterococcus and the species 
Staphylococcus aureus were also highly prevalent, this latter 
one was especially common in patients in low-risk clinical 
settings (i.e., non-intensive care units) [2], and 54% of all 
S. aureus isolated were resistant to methicillin [2].
The current gold standard method for the detection of 
nosocomial infections relies on microbiological culture. 
Cultures need to grow for a day or more before positive 
identification is possible and then further tests are needed to 
detect antibiotic resistance, which take a further 1–2 days. 
Hence, patients receive empiric broad-spectrum treatment 
before a specific diagnosis is made [6,7]. The overuse of broad- 
spectrum antibiotics can lead to: an increase in antimicrobial 
resistance (AMR); under-treatment of patients with resistant or 
untargeted pathogens; more adverse drug reactions; and an 
increased risk of opportunistic infections resulting from micro-
biome disruption [8–10].
Over the last decade, there have been substantial advances 
in next-generation sequencing technologies that have made it 
possible to use metagenomic sequencing for infection diag-
nosis. Significant reductions in cost and turnaround time 
coupled with increased data yields have enabled research 
and clinical laboratories to begin using metagenomic-based 
approaches for infection diagnosis, surveillance and outbreak 
management [11,12]. In response, a new field has developed, 
Clinical Metagenomics (CMg), which refers to the use of meta-
genomics to sequence all microbial and host genetic material 
present in patient samples for the diagnosis of infectious 
diseases [12] (a typical CMg pipeline is shown in Figure 1). 
Several studies have already demonstrated that 
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metagenomics-based diagnostics are superior to culture- 
based methodologies due to their broader detection capacity 
(i.e., bacteria, fungi, viruses including culturable/non- 
culturable and anaerobic aerobic pathogens in a single test), 
depth of information provided (i.e., AMR profile, virulence, 
genomic epidemiology), and rapid turnaround times (e.g., 
6 hours) [12,13]. However, there remain challenges that must 
be addressed before these new methodologies fully surpass 
those currently available, specifically: more automation is 
required in CMg pipelines to facilitate standardization; reagent 
and laboratory contamination issues need to be overcome; the 
abundance of host DNA greatly exceeds the abundance of 
pathogen DNA in clinical samples, making sensitive pathogen 
diagnosis difficult [13] without long sequencing run times; 
hence, rapid host-depletion and pathogen enrichment 
approaches are required.
In the coming years, CMg has the potential to play a key 
role in replacing current culture-based diagnostics. Here we 
review laboratory developed and commercially available CMg 
tests and their performance in comparison to current methods 
for the diagnosis of bloodstream infections and nosocomial 
pneumonia. We also look at what is in the CMg diagnostic 
pipeline and provide our opinion on the future directions for 
the field.
2. Clinical metagenomic methods for the detection 
of nosocomial infections
2.1. Bloodstream infections (sepsis)
Bloodstream infections (BSI) are frequent in healthcare set-
tings and can quickly develop into sepsis. Sepsis is currently 
defined as a life-threatening reaction caused by the dysregula-
tion of the host response to an infection that, if not detected 
at an early stage and managed quickly, can lead to end-stage 
organ dysfunction and death [14]. Mortality rates caused by 
sepsis are very high; globally, there are approximately 
50 million cases per year, of which 11 million are fatal 
(~20%) [15]. A large number of sepsis cases are hospital- 
acquired. Nosocomial BSIs are one of the most important 
hospital-acquired infections across all ages [16] and have 
been linked to: prolonged periods of hospitalization; increases 
in short- and long-term morbidity; and, in neonatal groups, 
chronic neurodevelopment problems [17–19]. A study in the 
USA showed that out of the total number of discharged sepsis 
patients, 25.9% of them had suffered health care sepsis 
(patients with prior healthcare environment exposures) and 
11.3% of them had hospital-acquired sepsis (developed at 
later points of hospitalization) [20].
Upon suspicion of sepsis, blood samples are taken and sent 
for blood culture [21]. Due to the long turnaround time for 
results [22], guidelines recommend administration of broad- 
spectrum antibiotics within the first hour of sepsis being 
suspected [21]. In one study, this meant that in approximately 
20% of sepsis cases, the wrong antibiotic treatment was given, 
resulting in a five-fold reduction in patient survival rate [23]. 
Furthermore, blood cultures have particularly poor sensitivity; 
it is estimated that cultures from 30%-50% of blood samples 
from sepsis patients are negative for potential causative 
agents [24]. Hence, there is an urgent need for more rapid 
and effective BSI diagnostics [25].
To date, several alternative molecular-based strategies have 
been evaluated for detection of the causative agents of sepsis; 
none of them have replaced culture-based methods, mainly 
because they did not provide equivalent or better sensitivity 
levels [6,26]. Recently, CMg-based methods have become 
commercially available and additional CMg tests have been 
developed in academic laboratories (see Table 1).
2.1.1. Cell-free DNA detection methods
One approach is to sequence cell-free DNA (cfDNA) in blood. 
Reports of large quantities of pathogen-derived cfDNA in 
plasma samples from sepsis patients [27–29] resulted in devel-
opment of cfDNA CMg methods. This approach diminishes the 
problem of host DNA contamination, which is relatively low in 
plasma compared to whole blood. However, since sequencing 
cfDNA does not provide whole genome coverage, reliable 
AMR gene/SNP detection isn’t possible as coverage breadth 
and depth isn’t sufficient [28,30]. Nonetheless, due to its sen-
sitivity and the speed of identifying the causative agents of 
sepsis, this approach still offers significant benefits over gold 
standard culture-based techniques [31].
A group at the Fraunhofer Institute for Interfacial 
Engineering and Biotechnology (Stuttgart, Germany) have 
been working on a cfDNA based CMg method for the detec-
tion of sepsis [28]. Blood is centrifuged to collect plasma, 
followed by cfDNA isolation and Illumina sequencing. All the 
data then go through an in silico post-processing step during 
which human sequences are removed and non-human 
sequences are taxonomically classified [28,31].
Recently, this method was validated compared to blood 
culture (BC) using plasma samples from patients with sus-
pected sepsis. Results showed a higher sensitivity in the meta-
genomic pipeline compared with the standard culture 
method; 72% of samples were positive using the CMg pipeline 
compared with 33% from cultures [31]. The reason for the 
increased diagnostic yield of this method compared to BC 
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● Between 5% and 20% of hospitalized patients worldwide are affected 
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gen numbers compared to BSI, are closer to implementation (2-5 
years).
● More pipeline automation and higher quality informatics are required 
for broad implementation of CMg methods.
372 L. MORAGUES-SOLANAS ET AL.
could either be that metagenomics detects pathogens missed 
by BC (true positives) [32], it is detecting the presence of 
cfDNA from past infections [32], possible reagent and environ-
mental contamination [33] if appropriate controls and 
thresholds were not used and/or cfDNA from bacteria in the 
body, e.g. the gut [34], that are not responsible for the sepsis 
(false positives). As the CMg approach was detecting patho-
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Figure 1. Laboratory and bioinformatics steps of a typical CMg pipeline. A typical CMg pipeline starts with the DNA/RNA extraction from the clinical sample. 
Optional steps of host DNA depletion and WGA can be added before and after the extraction, respectively. This is followed by preparing the nucleic acid for 
sequencing - the choice of library prep procedure depends on the sequencing technology and the concentration and type of nucleic acid. Taxonomic assignment 
and AMR screening is then performed, after optional human read removal, providing pathogen and AMR gene lists.
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28.3%. PCR testing could have been used to confirm the 
cfDNA results but wasn’t performed. The sensitivity of the 
test was also low, with only 63% of BC positive samples 
detected by CMg (Table 1), resulting in a positive predictive 
value of 10% [31]. The authors suggested that the pipeline had 
the potential to be used for identification of some AMR genes 
in plasma cfDNA. However, this was only possible in a few 
samples and for particular resistance genes – reliable AMR 
detection is not possible as genome coverage is typically too 
low (average genome coverage for the samples with AMR 
genes detected was 0.3x) [28]. According to a clinical expert 
panel, the CMg results would have led to a change in anti-
microbial treatment (de-escalation or escalation) in 53% of the 
cases thanks to its pathogen identification capacity and an 
overall reduction in the use of antimicrobials compared with 
using gold standard culture techniques [31]. It is unclear 
whether these changes in therapy would have been appro-
priate as both the specificity and sensitivity are relatively low.
Subsequently, this pipeline has been further optimized to 
include nanopore real-time sequencing (Oxford Nanopore 
Technologies (ONT)). This demonstrated that the detection of 
sepsis-causing bacteria in plasma from infected patients was 
possible within 5–6 hours of sample collection (as little as 
1 hour nanopore sequencing time). The authors did not report 
performance of this approach compared to BC on clinical 
samples. To achieve this rapid turnaround, sample positivity 
was based on as few as 1 pathogen read [35]. cfDNA from the 
plasma of healthy control groups was sequenced to define 
and then remove microbial contaminant reads and only 
pathogens on a sepsis-relevant pathogen list (SIQ-db) were 
reported [35]; however, one would assume that the low posi-
tivity detection threshold (1 pathogen read) presents a high 
risk of generating false positive results [33]. Also, sepsis rele-
vant pathogen cfDNA can be detected in healthy control 
plasma (e.g. cfDNA from gut or respiratory tract flora [34,36] 
e.g. Enterococcus faecalis or Streptococcus pneumoniae), so this 
approach for defining contamination may not be ideal.
The Karius® test (Karius, California, USA) is another example of 
how metagenomic sequencing of plasma cfDNA can be used for 
diagnosis of sepsis [37]. As with the Fraunhofer pipeline, this 
method begins with extraction of cfDNA from plasma, 
a sequencing library is constructed and sequenced using 
Illumina technology. The data are compared to an internal refer-
ence database containing a large number of microbial genomes; 
microbial reads are retained while reads that do not match the 
reference database are assumed to be human reads and 
excluded [37]. A validation study showed that this test identified 
approximately three times more positive cases than the gold 
standard culture methods [38], but the same caveats must 
apply regarding false positive detections as with the 
Fraunhofer test as this test showed relatively low specificity levels 
(62.7%) even after confirmatory testing was performed. 
Nonetheless, the most recent data published by the company 
showed 93.7% sensitivity (Table 1) when compared with gold 
standard culture methods, and the capability to deliver diagnos-
tic results on the day after sample receipt in 85% of cases [37–39]. 
The test has a slow turnaround time due to the requirement of 
sending the samples to the company (24 hours) plus the long 
sequencing run time required to get sufficient depth of 
sequence data for reliable pathogen detection (29 hours total 
test time) [37].
A recent study performed by Hogan et al. [40] compared 
the clinical impact achieved using the Karius® test with BC for 
diagnosing sepsis. The impact of using the Karius® test was 
considered as positive if it improved how the patients were 
clinically managed compared to BC – i.e. early diagnosis or 
appropriate change in antimicrobial therapy. Results sug-
gested that the test had a positive clinical impact in 7.3% of 
cases; however, it would have had a clinically negative impact 
in 3.7% of the cases – i.e. additional unnecessary diagnostic 
investigations or unnecessary treatment. In all other cases, the 
study concluded that using the Karius® test had no clinical 
impact compared to using the current gold standard meth-
odologies. This was either because the Karius® test identified 
the same microorganisms as conventional methods in 
a similar timeframe or, in most of the cases, it identified non- 
relevant microorganisms that did not need to be acted 
upon [40].
Another study comparing the Karius® test with BC found 
that 80% of samples that tested positive with Karius® identi-
fied clinically relevant pathogens that could help physicians 
target patient management. However, as seen in the previous 
study, the results also suggested that, overall, the Karius® test 
had a similar clinical impact as BC due to similar detection 
rates and turnaround times [41]. These studies suggest that 
BSI diagnostic methods based on cfDNA sequencing are not 
ready to replace current gold standard methods and question 
whether the currently limited benefits justify the ‘per-sample’ 
costs. Such studies also demonstrate that there is a need to 
identify the best way to integrate metagenomic methods into 
current testing systems.
2.1.2. Metagenomic approaches using whole blood
An alternative approach to plasma cfDNA sequencing is CMg 
sequencing of whole blood. This approach enables the direct 
identification of pathogens present in the blood and over-
comes some of the limitations associated with cfDNA tests, 
i.e., nonspecific detection of bacteria from the gut, mouth, etc., 
and inability to detect AMR [36]. However, these approaches 
are limited by the high levels of host genetic material relative 
to pathogen genetic material, which reduces sensitivity unless 
effective host depletion is applied [12,42–44]. Commercial 
host depletion methods are available including MolySiS 
(MolZym), Host Zero (Zymo) and NEBNext Microbiome 
Enrichment Kit (NEB) providing >90% removal of human 
DNA in blood [45–47]. However, faster, cheaper, more effective 
methods are required to facilitate implementation of CMg in 
whole blood at clinically relevant pathogen levels (often 
<10CFU/ml [48]).
The iDTECTTM Dx Blood test (PathoQuest SAS, Paris, 
France) is, to date, the only commercially available test that 
uses whole blood for the diagnosis of sepsis. Nucleic acid 
(DNA and RNA) is extracted from the whole-blood (using 
Molysis Basic 5 kit) and plasma (after DNase treatment to 
remove cfDNA) and subjected to a cDNA synthesis step (only 
for RNA) and multiple displacement amplification (MDA) fol-
lowed by library preparation and sequencing on an Ion Proton 
instrument. Human reads are removed by mapping to the 
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human reference genome. The remaining sequences are 
mapped against an in-house clinically relevant bacterial geno-
mic database which also allocates a score to the different 
reads obtained which is based on genome coverage, sequen-
cing depth, and alignment quality; only reads with high scores 
are considered as positive. The turnaround time for the test is 
2–3 days [49] and is only recommended for samples from 
immunosuppressed (neutropenic) adults [50]. The white cell 
count in blood samples from immunosuppressed patients is 
lower than in healthy individuals [51], which we assume 
improves test sensitivity.
In a study where this pipeline was used on samples from 
immunocompromised patients with suspected sepsis, the 
results showed that the method could identify clinically rele-
vant pathogens in a significantly higher number of samples 
than the gold standard culture-based methods (36% and 11%, 
respectively). Out of the total number of culture positive 
samples (11), 9 were confirmed by the sequencing pipeline, 
an overall sensitivity of 81.8%. The specificity was relatively 
low at 70% (but this may have been because BC was incor-
rect – no confirmatory PCRs were performed to answer this 
question). The study did report some problems with identify-
ing particular species due to insufficient sequence information 
and an inability to detect fungi or parasites due to limitations 
in the extraction procedure. No information on the detection 
of AMR was provided [49] but one would assume pathogen 
genome coverage is low using this approach; hence, AMR 
detection is not reliable. One important factor to be consid-
ered when interpreting the results is that a large proportion of 
culture negative samples were from patients receiving antimi-
crobial therapy at the time the samples were taken [49]. 
Hence, the detection of genomic DNA from non-viable cells 
[52] unable to grow in culture could account for the superior 
diagnostic yield reported using the metagenomic pipeline. It 
should also be noted that the test is not broadly applicable to 
BSI diagnosis as it can only be used reliably on immunocom-
promised patient blood samples.
2.1.3. Nanopore sequencing and bioinformatics analysis
Nanopore sequencing is now the method of choice for CMg 
pipelines as the data can be analyzed in real-time, significantly 
reducing turnaround time [53]. In 2015, the Chiu Group were 
one of the first to apply nanopore sequencing to blood 
enabling detection of different viral species in less than 
6 hours [54]. This method focused on viruses in plasma so 
wasn’t a CMg test for BSI (typically caused by bacteria/fungi); 
however, it was an early example of the potential of nanopore 
based CMg for blood applications. The same group recently 
published a CMg workflow for the detection of pathogens in 
body fluids (including blood) from infected patients using 
cfDNA. The method consists of an initial cfDNA extraction 
from plasma, followed by library preparation and Illumina or 
nanopore sequencing. After sequencing, all data is analyzed 
with the SURPI+ bioinformatics platform. When using 
Nanopore sequencing, the group showed that the detection 
of pathogens is achievable with this workflow in approxi-
mately 6 hours (compared to the 24 hours for Illumina). 
However, most of the reported data was from non-blood 
samples (e.g cerebrospinal fluid or joint fluid) so the efficacy 
of the test for BSI diagnosis is unknown [30].
Improvements in bioinformatics tools will also be impor-
tant for the implementation of CMg approaches for diagnosis 
of BSI. A number of tools for the rapid identification of the 
pathogens and AMR from metagenomic data are available 
[55]. Examples include SURPI+, Epi2Me, Bugseq, NanoOK and 
IDseq analytical tools [30,56–59]. IDseq is a good example of 
a new open source ‘easy-to-use’ bioinformatics tool that can 
be applied for CMg data analysis. This tool can rapidly remove 
all host data while providing fast taxonomic classification of 
the metagenomic reads. It is designed to make CMg analysis 
more open access and more user friendly [58]. However, the 
accuracy of these tools for read identification at the species 
level is variable and most tools report low levels of pathogen 
reads that aren’t present in the sample. These are typically 
removed in analysis pipelines by applying read thresholds 
below which detection is unreliable. More accurate species 
level read identification that avoids the need for the use of 
thresholds would be preferrable.
2.1.4. Methods in development
Additional CMg BSI diagnostic tests are in development. Day 
Zero Diagnostics (Boston, USA) are developing a rapid nanopore 
sequencing-based CMg pipeline for whole blood BSI pathogen 
and AMR identification. This will be achieved using their 
Blood2Bac and Keynome technologies to enrich the pathogen 
DNA present in samples (i.e. deplete human DNA) and predict 
AMR profiles in the genomic sequences obtained, respectively 
[60]. IDbyDNA (California, USA) is also aiming to develop a CMg 
test for the diagnosis of BSI and other infections using Illumina 
sequencing technology. They will use their Explify® platform, 
a proprietary database which can process large amounts of 
metagenomic data and rapidly identify microorganisms, to 
detect BSI using CMg data from whole blood [61,62]. The com-
pany has developed CMg tests for other tissue samples, e.g., 
urinary-tract infections. Human DNA is depleted using a saponin- 
based method followed by DNA extraction, library preparation 
and Illumina sequencing [63]. The Center for Next Generation 
Precision Diagnostics at the University of California–San 
Francisco is currently offering metagenomic diagnostic services 
for the detection of meningitis, and they are planning to expand 
this service for the detection of BSI [64]. This technology includes 
a microbial enrichment step that consists of either adding anti-
bodies to remove host-methylated DNA for pathogen identifica-
tion, or adding DNAse to enable production of RNA libraries. The 
genomic material from the tissue samples is then amplified for 
library construction; libraries are sequenced on an Illumina HiSeq 
instrument. CMg data are analyzed using SURPI+, an automated 
computational pipeline that removes any remaining host geno-
mic data and identifies the pathogens present [65].
2.2. Respiratory tract infections (pneumonia)
Every year in England, 300,000 patients acquire 
a healthcare-associated infection, of those the most common 
are lower respiratory tract infections (LRTIs) [66]. Nosocomial 
LRTIs include hospital-acquired pneumonia (HAP) and 
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ventilator-associated pneumonia (VAP), caused by bacterial 
contamination of the ventilator tubes and liquid traps. On 
average, nosocomial pneumonia is estimated to extend 
patient hospitalization time by more than 1 week and has 
a mortality rate of up to 70% [67]. A diversity of pathogens 
cause HAP and VAP; globally Enterobacterales, Pseudomonas 
aeruginosa, Staphylococcus aureus and Acinetobacter bauman-
nii are the most common [68,69], while the importance of 
other bacterial/fungal species varies geographically [70,71].
Currently, patients with suspected nosocomial pneumonia 
are diagnosed using microbiological culture. As for BSIs, the 
long turnaround time for culture results leads to poor anti-
microbial stewardship, increased mortality, prolonged hospital 
stays, and added costs [72,73]. In routine practice, only circa 
30% of respiratory samples tested show clear microbial 
growth in culture [74], making it difficult to provide 
a definitive diagnosis for all patients. The most common issues 
are a) some common pathogens, e.g., Streptococcus pneumo-
niae and Haemophilus influenzae, are difficult to grow and can 
die between sampling and testing; b) the clinical significance 
of some common respiratory bacterial species is subjective 
and requires experienced judgment; c) it is difficult to make 
a correct diagnosis in patients with multiple previous pathol-
ogies [73]. CMg has the potential to replace culture for the 
diagnosis for LRTIs and several studies have recently applied 
this approach (Table 2) with comparable results in culture for 
identifying the causative agents of LRTI but in a significantly 
shorter timeframe while providing additional clinically useful 
information [57,75,76].
2.2.1. Detection of LRTI using short-read sequencing
A recent study by Langelier et al. [75] used CMg to test 
samples from 92 adults that had been admitted to the inten-
sive care unit (ICU) with acute respiratory failure; the cohort 
had been divided into four groups for which: (i) LRTI had been 
defined by both clinical criteria and culture methods; (ii) there 
was no evidence of LRTI and an alternative explanation for 
respiratory failure was given; (iii) LRTI had been defined by 
clinical criteria but with negative results from cultures; (iv) the 
cause of respiratory failure was unclear. While most CMg 
pipelines typically target DNA, this pipeline sequenced both 
DNA and RNA. Specifically, after nucleic acid extraction, RNA 
was reverse transcribed to generate cDNA and used to con-
struct sequencing libraries using the NEBNext Ultra II Library 
Prep Kit (New England Biolab). DNA underwent barcoding 
using Nextera library preparation kit (Illumina). An additional 
step was used to selectively deplete/remove the highly abun-
dant human mitochondrial cDNA by hybridization (DASH) [77]. 
The final DNA-seq and RNA-seq libraries were sequenced 
using an HiSeq 4000 Illumina platform. This approach allowed 
detection of bacteria, fungi and DNA and RNA viruses and, at 
the same time, enriched the samples for actively transcribing 
microbes versus latent taxa. The authors also developed an in- 
house bioinformatic pipeline to align reads and identify bac-
terial taxa. The pipeline was based on a model that distin-
guishes pathogens from commensal microorganisms using 
two algorithms: (i) a rule-based model (RBM) optimized for 
detecting well-known respiratory pathogens and (ii) a flexible 
logistic regression model (LRM) to detect novel or atypical 
species. Using the sequencing and bioinformatic pipeline 
described, 44 samples were tested (26 definite positive and 
18 definitive negative samples), 20 in a derivation set and 24 
in a validation set. Sensitivity was 100% as all 38 pathogens 
identified from clinician-ordered microbiologic tests were 
detected in the 26 positive samples. Specificity was lower 
(83%, 15/18) as S. pneumoniae was detected in 2 negative 
samples and H. influenzae in one negative sample. When 
tested on the derivation and validation sets, the RBM achieved 
an accuracy for pathogen detection of 98.8% and 95.5%, 
respectively. The LRM model, employing a machine learning 
approach to distinguish respiratory pathogens from commen-
sals, was firstly trained on the derivation set and then tested 
on the validation set, achieving an AUC of 0.91 (95% CI, 0.83–-
0.97) for pathogen identification. Both models suffered when 
multiple pathogen species at several different magnitudes of 
abundance were present in the clinical sample. The turn-
around time for the pipeline was not reported; however, as 
DNA and RNA libraries were made, host depletion wasn’t 
performed and Illumina sequencing was used, the process 
would have taken 1–2 days.
Li et al. [78] developed a CMg method for diagnosis of 
infection in bronchoalveolar lavage (BAL) samples from 
patients in the intensive care unit (ICU). They used 
a TIANamp Micro DNA Kit to extract DNA and a BGISEQ-50 
platform for short-read metagenomic sequencing and ana-
lyzed the data with a Burrows−Wheeler Alignment (BWA), 
a tool based on Burrows–Wheeler Transform to efficiently 
align short sequencing reads against a large reference 
sequence, allowing mismatches and gaps [79]. The study was 
based on 35 BAL samples from 32 ICU patients with respira-
tory failure. The samples produced a relatively small number 
of reads, as BAL is a dilute sample with low pathogen num-
bers. However, in terms of microbial species identification 
(AMR was not reported due to low pathogen coverage), the 
study reported 89% sensitivity and 74% specificity when com-
pared with culture results. The CMg pipeline detected 
Table 2. Summary of the main CMg pipelines for the diagnosis of LRTIs.
Sensitivity Specificity
Turnaround 
time Microorganisms detected Bioinformatics methods used
Sequencing 
Technology References
Langelier et al. (short- 
reads)
100% 83% Not 
reported
Bacterial, viral and fungal 
species
In-house with machine learning 
predictive model
Illumina HiSeq [75]
Li et al. (short-reads) 89% 74% Not 
reported
Bacterial, viral (DNA) and 
fungal species
In house based on Burrows-Wheeler 
alignment tool
BGISEQ-50 [78]
Yang et al. (long- 
reads)
100% 66% 6–8 hours Bacterial and fungal species Epi2ME ONT platform ONT MinION [76]
Charalampous et al. 
(long-reads)
100% 100% 6 hours Bacterial and fungal species Epi2ME ONT platform ONT MinION [57]
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pathogens in 13 samples where culture was negative – in 11 
cases the CMg results led to a change in antibiotic treatment. 
Insufficient data were presented to determine whether these 
changes to therapy were appropriate. The turnaround time for 
this CMg method was not reported.
2.2.2. Rapid metagenomic detection of LRTIs
Charalampous et al. [57] was the first study to utilize rapid 
nanopore sequencing based CMg for the characterization of 
bacterial LRTIs. The pipeline included: DNA extraction, with 
a bead-beating step for improved microbial lysis; an efficient 
differential lysis-based host DNA depletion protocol using 
saponin; library preparation and sequencing on the MinION; 
and real-time data analysis on the Epi2me platform (ONT). The 
optimized pipeline was tested on 41 respiratory samples 
achieving more than 96.6% sensitivity and 41.7% specificity 
compared with culture; the turnaround time from sample 
collection to results was only 6 hours, including 2 hours 
sequencing time. After PCR validation of discordant results, 
the authors reported 100% sensitivity and specificity.
The host DNA depletion step included was necessary for 
removal of the large amounts of the human DNA present and 
ensuring that the pipeline had high resolution in a short turn-
around time. The depletion method did not inadvertently 
remove DNA from common respiratory pathogens, except for 
S. pneumoniae [57]. The authors suggest that this is probably 
because S. pneumoniae can autolyze in culture and in clinical 
samples, and therefore can be lost during the depletion step. 
This is also a known issue for culture-based methods.
The CMg pipeline accurately detected mecA in both MRSA 
samples, sul1 and dfrA12 or dfrA17 in both co-trimoxazole- 
resistant E. coli, aac(3’)-IIa in a tobramycin-resistant E. coli 
and blaTEM variants in two amoxicillin-resistant E. coli and 
two amoxicillin-resistant H. influenzae. However, multiple 
AMR genes were found in CMg data from some samples 
where the isolates grown were unlikely to have hosted these 
genes [57]. This issue could be solved with a bioinformatics 
tool based on ‘genomic neighbor typing’, i.e. RASE (resistance- 
associated sequence elements). This tool can align CMg reads 
to a database of pathogen lineages with known resistance/ 
susceptibility profiles to find the closest match [80], thereby 
predicting AMR. This approach was applied to CMg data from 
the Charalampous study enabling accurate prediction of AMR 
in S. pneumoniae (75% sensitivity and 100% specificity) posi-
tive samples.
Two hours of sequence data from host depleted respiratory 
samples containing E. coli and S. aureus (MRSA) were used for 
reference-based metagenomic assemblies, resulting in 48x and 
34x genome coverage, respectively. Coverage increased to 166x 
for E. coli and 229x for S. aureus after 48 hours sequencing, 
resulting in assemblies containing 72 and 33 contigs, respec-
tively. This demonstrates the power of CMg that includes effi-
cient host depletion, providing whole pathogen genomes that 
can be utilized for nosocomial outbreak detection and imple-
mentation of appropriate infection control measures.
Yang et al. [40], applied a nanopore CMg pipeline, based on 
the Charalampous et al. [57] method, to ETA samples from 22 
VAP patients. The authors report a turnaround time of 6 − 8 h 
including the DNA extraction step, saponin-based host DNA 
depletion, library preparation, and sequencing. The pipeline 
had a sensitivity of 100% and a specificity of 66% (not count-
ing Candida spp as respiratory pathogens) compared to cul-
ture. All the samples reported as positive by culture method 
were detected by the pipeline. In four cases with resistant 
clinical isolates, the pipeline detected AMR genes correspond-
ing to the antibiograms. In culture-negative clinically diag-
nosed pneumonia samples, CMg detected potential bacterial 
pathogens in 1/5 of cases and Candida spp in 3/5 cases. In this 
study, low levels of pathogens, e.g., S. aureus, H. influenzae, or 
S. pneumoniae, were detected by CMg in samples from 
patients with no evidence of pneumonia. This highlights the 
need for caution in interpreting CMg results because the 
presence of pathogens does not necessarily mean they are 
causing infection. However, the same level of caution one 
would apply given the low-level detection of these patho-
bionts by culture.
3. Conclusion
In this article, we review the state-of-the-art in commercial and 
laboratory developed CMg pipelines for the diagnosis of blood-
stream infection and nosocomial pneumonia. These tests have the 
potential to overcome the main disadvantages of culture-based 
methodologies, i.e., turnaround time, while also offering a more 
comprehensive diagnostic approach capable of detecting any 
pathogen in a single test. CMg tests for BSI typically target 
cfDNA, mainly because the ratio of human:pathogen DNA is 
lower in plasma than in whole blood. This approach has high 
sensitivity for the detection of pathogens but specificity is low, 
hence more development is required before CMg will replace 
blood culture. Nosocomial pneumonia CMg pipelines, on the 
other hand, have high sensitivity and specificity and are closer 
to clinical implementation. This is because there are higher patho-
gen loads and the ratio of human:pathogen DNA is lower. Host 
depletion methods have also been developed that enable CMg 
pipelines to provide whole pathogen genomes within hours. This 
rich data enables rapid pathogen and AMR gene identification 
while at the same time providing the information necessary to 
identify and control hospital transmission. More work is required 
to improve AMR detection, but the advantages these tests pro-
vide mean it is likely we will see them implemented in hospitals 
alongside culture in the near future.
4. Expert opinion
Rapid, accurate methods for the diagnosis of BSI directly from 
blood are the holy grail for infectious disease diagnostic devel-
opers. The SeptiFast test (PCR-based assay) from Roche was 
the first to enter the market but it was too cumbersome, 
prone to contamination and not sufficiently sensitive as the 
panel of pathogens detected wasn’t broad enough. There still 
hasn’t been a successful rapid BSI diagnostic test developed 
over a decade later. CMg clearly shows potential in this area, 
as it has the necessary speed and breadth of detection; how-
ever, the current cfDNA approaches suffer from low specificity 
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and they cannot provide reliable AMR data. Whole blood 
based CMg methods may have greater potential, provided 
that highly efficient host depletion or pathogen enrichment 
is performed. Such steps add complexity and potential bias, 
but if rapid, simple, automatable approaches can be devel-
oped, whole blood CMg is likely to be superior to cfDNA 
approaches. This approach is being pursued by Day Zero 
Diagnostics, who have recently secured significant funding 
to develop it. The biggest challenge of reliably detecting as 
few as 1 colony forming unit per milliliter of blood will still 
remain. To achieve the same sensitivity as culture, large 
volumes of blood need to be tested (5–20 ml) and whole 
genome amplification (WGA) will be required. This is techni-
cally challenging, as the more blood you test, the more human 
DNA you have to remove and WGA is prone to contamination.
Nosocomial pneumonia is a major problem in hospitals glob-
ally and as important as BSI; however, accurate diagnostic test 
development is significantly easier than for BSI. This is because 
there are significantly more pathogens per milliliter of respiratory 
sample (often >105). There are several rapid accurate PCR-based 
LRTI tests available on the market that provide results within hours 
(e.g., Biofire FilmArray Pneumonia panel). However, PCR-based 
tests are hampered by lack of breadth to test for all the relevant 
pathogens and AMR genes. CMg has a technological advantage 
over PCR, i.e., breadth of pathogen and AMR detection, and might 
be the technology of choice for LRTI diagnosis in the near future. 
The challenge of host DNA is similar to blood, but this has been 
solved by test developers using host depletion or deep sequen-
cing. A challenge in respiratory samples not encountered in whole 
blood metagenomic approaches is commensal microbial lung 
flora. These microbes use up sequencing reads, are closely related 
to some respiratory pathogens leading to false positives (e.g., 
Streptococcus pneumoniae) and harbor resistance genes that can 
be incorrectly associated with pathogens in the same sample. For 
CMg to be successfully implemented for LRTI diagnosis, pipelines 
must be faster and simplified using automation. Advances in 
informatics are also required, to improve read identification and 
AMR detection. Acquired resistance genes need to be linked to the 
pathogen from which they originate using tools like Scagaire [81] 
(filter resistance genes to only report those relevant to the identi-
fied pathogen) and resistance or, even better, susceptibility needs 
to be rapidly identifiable given relatively low genome coverage, 
using methods such as RASE [80].
We believe that CMg will begin being implemented in hos-
pitals for the diagnosis of LRTIs in the next couple of years, 
alongside culture. Depending on the success of the early adop-
ters and the pace of CMg pipeline improvement, CMg for LRTI 
may be widely implemented in wealthier countries within 
5 years, eventually replacing culture in the longer term. CMg 
pipelines for the diagnosis of BSI will likely take longer, but we 
may see the first tests being clinically evaluated within 5 years.
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